INVESTOR RELATIONS · PRE-SEED

Narrow the claim. Earn the category.

NovusTex is raising a milestone round to turn an engineered human-tissue platform into a pilot-ready, diligence-ready product — with every claim mapped to a gate you can audit.

THE INVESTMENT CASE

Four gates. Ninety days. Let evidence decide.

auditable gates: build, biology, response, pilot readiness

days from capital to a pilot-ready, diligence-ready product

100+

publications screened to build the design foundation

printers to buy — an asset-light, vendor-agnostic model

Regulators are moving toward human-relevant New Approach Methodologies — FDA's 2026 draft guidance, a September 2026 rule clarifying nonanimal methods, and NIH's new ORIVA office. NasalCart™ is built to meet that bar, not ride the headline.

Request the deck

THE THESIS

Four things have to be true — and each one can be tested.

Route relevance

Intranasal delivery is active across local, systemic, emergency and CNS applications.

ii.

Decision gap

Barrier, inflammatory and structural responses are still fragmented across model types.

iii.

Standardization

A multi-layer construct creates value only if it is reproducible and tied to a program decision.

iv.

Commercial pull

Teams pay when the result changes formulation or device choices before costlier studies.

90-DAY RISK RETIREMENT

The round buys evidence, not ambition.

GATE 01

Build lock

Signed manufacturing scope, locked construct specification, lot traceability and repeatable handling.

GATE 02

Multi-layer biology

Viability and architecture retained across epithelium, stroma and cartilage through day 7.

GATE 03

Phenotype + response

Cartilage phenotype, matrix stability, inflammation and degradation readouts in place.

GATE 04

Pilot readiness

Controls separate reproducibly; SOPs, QC package and decision-ready report complete.

Day 90: advance, iterate — or stop. The stop rule is the point.

USE OF FUNDS

Four workstreams. One proof engine.

Capital is sequenced to the gates. Higher-fidelity tiers and scale are funded by pilot revenue and later rounds — only after Core evidence exists.

Manufacturing + partner lock SOW · construct · QC · reproducibility

Pilot assays + validation controls · phenotype · inflammation · degradation

IP, contracts + operations rights · data · diligence room

Runway + customer conversion full-time execution · pilot pipeline

12-MONTH TRAJECTORY

No feature without a buyer who needs it.

MONTHS 0–3

Lock + build

Select partner, sign scope, tri-layer build, Day-90 gates.

MONTHS 3–6

Pilot + learn

First paid RUO pilots; measure cost and turnaround.

MONTHS 6–9

Repeat + standardize

Repeat customers; freeze the first standardized package.

MONTHS 9–12

Expand + finance

Core+ if Core earns pull; institutional seed on evidence.

DEFENSIBILITY

The moat compounds with every pilot.

Specification control Acceptance logic Context of use Assay workflow Confidential know-how Portable vendor rights Versioned decision data

No issued-patent claim is made. Patentable surfaces will be identified and filed as evidence accumulates.

REQUEST INVESTOR MATERIALS

Get the deck, the technical brief and the roadmap.

Shared under confidentiality with accredited and institutional investors. Every traction claim maps to a document in diligence.